This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kiernan, R. E.
Right arrow Articles by Freed, E. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kiernan, R. E.
Right arrow Articles by Freed, E. O.

 Previous Article  |  Next Article 

Journal of Virology, June 1999, p. 4728-4737, Vol. 73, No. 6
0022-538X/99/$04.00+0

Reversion of a Human Immunodeficiency Virus Type 1 Matrix Mutation Affecting Gag Membrane Binding, Endogenous Reverse Transcriptase Activity, and Virus Infectivity

Rosemary E. Kiernan,dagger Akira Ono, and Eric O. Freed*

Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0460

Received 29 December 1998/Accepted 12 March 1999

We previously characterized mutations in the human immunodeficiency virus type 1 matrix (MA) protein that displayed reduced infectivity in single-round assays, defects in the stable synthesis of viral DNA in infected cells, and impaired endogenous reverse transcriptase activity. The mutants, which contained substitutions in a highly conserved Leu at MA amino acid 20, also increased binding of Gag to membrane. To elucidate further the role of MA in the virus replication cycle, we have characterized a viral revertant of an amino acid 20 mutant (20LK). The revertant virus, which replicates with essentially wild-type kinetics in H9 cells, contains second-site compensatory changes at MA amino acids 73 (Eright-arrowK) and 82 (Aright-arrowT), while retaining the original 20LK mutation. Single-cycle infectivity assays, performed with luciferase-expressing viruses, show that the 20LK/73EK/82AT triple mutant displays markedly improved infectivity relative to the original 20LK mutant. The stable synthesis of viral DNA in infected cells is also significantly increased compared with that of 20LK DNA. Furthermore, activity of revertant virions in endogenous reverse transcriptase assays is restored to near-wild-type-levels. Interestingly, although 20LK/73EK/82AT reverses the defects in replication kinetics, postentry events, and endogenous reverse transcriptase activity induced by the 20LK mutation, the reversion does not affect the 20LK-imposed increase in Gag membrane binding. Mutants containing single and double amino acid substitutions were constructed, and their growth kinetics were examined. Only virus containing all three changes (20LK/73EK/82AT) grew with significantly accelerated kinetics; 73EK, 73EK/82AT, and 20LK/82AT mutants displayed pronounced defects in virus particle production. Viral core-like complexes were isolated by sucrose density gradient centrifugation of detergent-treated virions. Intriguingly, the protein composition of wild-type and mutant detergent-resistant complexes differed markedly. In wild-type and 20LK complexes, MA was removed following detergent solubilization of the viral membrane. In contrast, in revertant preparations, the majority of MA cosedimented with the detergent-resistant complex. These results suggest that the 20LK/73EK/82AT mutations induced a significant alteration in MA-MA or MA-core interactions.

* Corresponding author. Mailing address: Bldg. 4, Rm. 307, NIAID, NIH, Bethesda, MD 20892-0460. Phone: (301) 402-3215. Fax: (301) 402-0226. E-mail: EFreed{at}nih.gov.

dagger Present address: IGH, CNRS-UPR 1142, Montpellier, France.

Journal of Virology, June 1999, p. 4728-4737, Vol. 73, No. 6
0022-538X/99/$04.00+0


This article has been cited by other articles:

  • Ono, A., Ablan, S. D., Lockett, S. J., Nagashima, K., Freed, E. O. (2004). Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc. Natl. Acad. Sci. USA 101: 14889-14894 [Abstract] [Full Text]  
  • Perez-Caballero, D., Hatziioannou, T., Martin-Serrano, J., Bieniasz, P. D. (2004). Human Immunodeficiency Virus Type 1 Matrix Inhibits and Confers Cooperativity on Gag Precursor-Membrane Interactions. J. Virol. 78: 9560-9563 [Abstract] [Full Text]  
  • Tang, S., Murakami, T., Cheng, N., Steven, A. C., Freed, E. O., Levin, J. G. (2003). Human Immunodeficiency Virus Type 1 N-Terminal Capsid Mutants Containing Cores with Abnormally High Levels of Capsid Protein and Virtually No Reverse Transcriptase. J. Virol. 77: 12592-12602 [Abstract] [Full Text]  
  • Callahan, E. M., Wills, J. W. (2003). Link between Genome Packaging and Rate of Budding for Rous Sarcoma Virus. J. Virol. 77: 9388-9398 [Abstract] [Full Text]  
  • Forshey, B. M., von Schwedler, U., Sundquist, W. I., Aiken, C. (2002). Formation of a Human Immunodeficiency Virus Type 1 Core of Optimal Stability Is Crucial for Viral Replication. J. Virol. 76: 5667-5677 [Abstract] [Full Text]  
  • Chen, S. S.-L., Lee, S.-F., Wang, C.-T. (2001). Cellular Membrane-Binding Ability of the C-Terminal Cytoplasmic Domain of Human Immunodeficiency Virus Type 1 Envelope Transmembrane Protein gp41. J. Virol. 75: 9925-9938 [Abstract] [Full Text]  
  • Tang, S., Murakami, T., Agresta, B. E., Campbell, S., Freed, E. O., Levin, J. G. (2001). Human Immunodeficiency Virus Type 1 N-Terminal Capsid Mutants That Exhibit Aberrant Core Morphology and Are Blocked in Initiation of Reverse Transcription in Infected Cells. J. Virol. 75: 9357-9366 [Abstract] [Full Text]  
  • Callahan, E. M., Wills, J. W. (2000). Repositioning Basic Residues in the M Domain of the Rous Sarcoma Virus Gag Protein. J. Virol. 74: 11222-11229 [Abstract] [Full Text]  
  • Ono, A., Orenstein, J. M., Freed, E. O. (2000). Role of the Gag Matrix Domain in Targeting Human Immunodeficiency Virus Type 1 Assembly. J. Virol. 74: 2855-2866 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»